

Emma I Andersson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4304586/publications.pdf>

Version: 2024-02-01

11
papers

638
citations

933447

10
h-index

1281871

11
g-index

11
all docs

11
docs citations

11
times ranked

1367
citing authors

#	ARTICLE	IF	CITATIONS
1	Aggressive natural killer-cell leukemia—mutational landscape and drug profiling highlight JAK-STAT signaling as therapeutic target. <i>Nature Communications</i> , 2018, 9, 1567.	12.8	107
2	Novel activating STAT5B mutations as putative drivers of T-cell acute lymphoblastic leukemia. <i>Leukemia</i> , 2014, 28, 1738-1742.	7.2	90
3	The analysis of clonal diversity and therapy responses using STAT3 mutations as a molecular marker in large granular lymphocytic leukemia. <i>Haematologica</i> , 2015, 100, 91-99.	3.5	88
4	Somatic mutations in clonally expanded cytotoxic T lymphocytes in patients with newly diagnosed rheumatoid arthritis. <i>Nature Communications</i> , 2017, 8, 15869.	12.8	83
5	Discovery of novel drug sensitivities in T-PLL by high-throughput ex vivo drug testing and mutation profiling. <i>Leukemia</i> , 2018, 32, 774-787.	7.2	75
6	Actionable perturbations of damage responses by TCL1/ATM and epigenetic lesions form the basis of T-PLL. <i>Nature Communications</i> , 2018, 9, 697.	12.8	73
7	Novel somatic mutations in large granular lymphocytic leukemia affecting the STAT-pathway and T-cell activation. <i>Blood Cancer Journal</i> , 2013, 3, e168-e168.	6.2	56
8	Genomic landscape characterization of large granular lymphocyte leukemia with a systems genetics approach. <i>Leukemia</i> , 2017, 31, 1243-1246.	7.2	33
9	Novel drug candidates for blast phase chronic myeloid leukemia from high-throughput drug sensitivity and resistance testing. <i>Blood Cancer Journal</i> , 2015, 5, e309-e309.	6.2	19
10	Novel TBL1XR1, EPHA7 and SLFN12 mutations in a Sezary syndrome patient discovered by whole exome sequencing. <i>Experimental Dermatology</i> , 2014, 23, 366-368.	2.9	12
11	Divergent roles for antigenic drive in the aetiology of primary versus dasatinib-associated CD8+ TCR-V β 2+ expansions. <i>Scientific Reports</i> , 2018, 8, 2534.	3.3	2